FGFR2 fusions and rearrangements
A broken-and-rejoined FGFR2 gene that drives about one in eight intrahepatic bile duct cancers and can be switched off with pills.
Detected by RNA or DNA sequencing; partners are diverse (BICC1 most common). Pemigatinib (ORR 37%) and futibatinib (ORR 42%) are approved; acquired resistance arises through FGFR2 kinase-domain mutations (N550, V565 gatekeeper) that next-generation inhibitors (tinengotinib, RLY-4008 lirafugratinib) target. Hyperphosphataemia is the class effect.
Pages like this
not linked directly; found by shared links- TrialFIGHT-202
Shares Pemigatinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- TrialFIRST-308
Shares Tinengotinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- TrialFOENIX-CCA2
Shares Futibatinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- CompanyTransThera Sciences
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
- CompanyTaiho Pharmaceutical (Otsuka)
Shares Futibatinib, Biliary tract cancer (cholangiocarcinoma).
- TermIntrahepatic, perihilar, distal and gallbladder cancer
- CompanyIncyte
Shares Pemigatinib, Biliary tract cancer (cholangiocarcinoma).
- PersonTanios Bekaii-Saab